FPAS
IKT icon

Focus Partners Advisor Solutions’s Inhibikase Therapeutics IKT Stock Holding History

Focus Partners Advisor Solutions’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$20K Buy
11,886
+1,167
+11% +$2.07K ﹤0.01% 1242
2025
Q4 		$22K Buy
10,719
+11
+0.1% +$18 ﹤0.01% 1081
2025
Q3 		$17.3K Hold
10,708
– – ﹤0.01% 1130
2025
Q2 		$20.9K Buy
+10,708
New +$21K ﹤0.01% 1090

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Focus Partners Advisor Solutions's IKT Position: Q1 2026 in Review

Focus Partners Advisor Solutions increased its Inhibikase Therapeutics (IKT) stake by 11% in Q1 2026, buying an estimated $2.07K and bringing the position to 11,886 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #1242.

Focus Partners Advisor Solutions first reported a position in IKT in Q2 2025 and has held it in 4 quarters since. The position peaked at $22K in Q4 2025. 104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • Focus Partners Advisor Solutions held 11,886 shares of Inhibikase Therapeutics worth $20K as of Q1 2026.
  • Focus Partners Advisor Solutions bought 1,167 Inhibikase Therapeutics shares in Q1 2026, an estimated $2.07K.
  • Inhibikase Therapeutics made up ﹤0.01% of Focus Partners Advisor Solutions's portfolio in Q1 2026, its #1242 holding.
  • Focus Partners Advisor Solutions first reported a position in Inhibikase Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Focus Partners Advisor Solutions's Inhibikase Therapeutics position peaked at $22K in Q4 2025.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on Focus Partners Advisor Solutions's 13F filing for Q1 2026, filed 13 May 2026.